{"data":[{"accessionNo":"0000902664-26-003524","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Lynx1 Capital Management LP","reportingCik":null,"personType":"PN","sharesOwned":15423691,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-26-003524","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Weston Nichols","reportingCik":null,"personType":"IN","sharesOwned":15423691,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001231919-26-000920","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":11383696,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001231919-26-000920","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":11383696,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001231919-26-000920","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":11383696,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001231919-26-000920","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":11383696,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":7600000,"percentOfClass":6.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":7600000,"percentOfClass":6.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":7600000,"percentOfClass":6.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000022","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"William Blank","reportingCik":null,"personType":"HC,IN","sharesOwned":7600000,"percentOfClass":6.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000895421-26-000231","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":8862002,"percentOfClass":8,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000895421-26-000231","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Morgan Stanley Capital Services LLC","reportingCik":null,"personType":"BD,CO","sharesOwned":8718000,"percentOfClass":7.9,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000895421-26-000231","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Morgan Stanley & Co. LLC","reportingCik":null,"personType":"BD,CO","sharesOwned":134047,"percentOfClass":0.1,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002012383-26-002217","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":7678906,"percentOfClass":6.9,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000018","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-05-12","reportingPerson":"William Blank","reportingCik":null,"personType":"HC,IN","sharesOwned":5550000,"percentOfClass":5,"filedAt":"2026-05-19","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000018","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-05-12","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":5550000,"percentOfClass":5,"filedAt":"2026-05-19","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000018","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-05-12","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":5550000,"percentOfClass":5,"filedAt":"2026-05-19","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0002050709-26-000018","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-05-12","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":5550000,"percentOfClass":5,"filedAt":"2026-05-19","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000919574-26-003216","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Sirenia Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":23505000,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000919574-26-003216","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Alex Silverstein","reportingCik":null,"personType":"HC,IN","sharesOwned":23505000,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000919574-26-003479","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":169096,"percentOfClass":0.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000919574-26-003479","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":169096,"percentOfClass":0.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000919574-26-003479","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":"12529R107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":169096,"percentOfClass":0.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000814133-26-000050","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001662579","issuerName":"C4 Therapeutics Inc","ticker":"CCCC","cusip":"12529R107","securityClass":"COM STK","eventDate":"2026-03-31","reportingPerson":"Wasatch Advisors LP","reportingCik":null,"personType":"IA","sharesOwned":4581761,"percentOfClass":4.7,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-26-001046","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Lynx1 Capital Management LP","reportingCik":null,"personType":"PN","sharesOwned":7098133,"percentOfClass":7.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-26-001046","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Weston Nichols","reportingCik":null,"personType":"IN","sharesOwned":7098133,"percentOfClass":7.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000947871-26-000188","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"OrbiMed Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":883534,"percentOfClass":1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000947871-26-000188","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"OrbiMed Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":521368,"percentOfClass":0.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Guy Levy","reportingCik":null,"personType":"IN","sharesOwned":10334114,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Capital Group, LLC","reportingCik":null,"personType":"OO","sharesOwned":10361860,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Capital Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":10334114,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":10334114,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Capital Master Fund, L.P.","reportingCik":null,"personType":"FI","sharesOwned":10361860,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Capital, LLC","reportingCik":null,"personType":"OO","sharesOwned":10361860,"percentOfClass":9.99,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Private Equity GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":6072822,"percentOfClass":5.9,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus PE GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":6072822,"percentOfClass":5.9,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001213900-26-015656","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Soleus Private Equity Fund III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6072822,"percentOfClass":5.9,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000895421-26-000033","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":8974191,"percentOfClass":9.3,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000895421-26-000033","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley & Co. LLC","reportingCik":null,"personType":"BD,CO","sharesOwned":8897942,"percentOfClass":9.2,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000947871-25-001020","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"OrbiMed Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":3568346,"percentOfClass":5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000947871-25-001020","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"OrbiMed Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":1666800,"percentOfClass":2.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000814133-25-000117","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001662579","issuerName":"C4 Therapeutics Inc","ticker":"CCCC","cusip":null,"securityClass":"COM STK","eventDate":"2025-09-30","reportingPerson":"Wasatch Advisors LP","reportingCik":null,"personType":"IA","sharesOwned":4852741,"percentOfClass":6.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001346824-25-000025","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-17","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":9441256,"percentOfClass":9.9,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001346824-25-000025","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-17","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":9441256,"percentOfClass":9.9,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001346824-25-000025","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-17","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":9441256,"percentOfClass":9.9,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0001346824-25-000025","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-17","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":9441256,"percentOfClass":9.9,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000950130-25-000220","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":null,"personType":"PN","sharesOwned":6060000,"percentOfClass":6.25,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000950130-25-000220","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":991188,"percentOfClass":1.07,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000950130-25-000220","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":null,"personType":"PN","sharesOwned":120722,"percentOfClass":0.13,"filedAt":"2025-10-24","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-25-004471","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":22647647,"percentOfClass":9.9,"filedAt":"2025-10-20","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-25-004471","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":22647647,"percentOfClass":9.9,"filedAt":"2025-10-20","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"},{"accessionNo":"0000902664-25-004471","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001662579","issuerName":"C4 Therapeutics, Inc.","ticker":"CCCC","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-17","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":22647647,"percentOfClass":9.9,"filedAt":"2025-10-20","canonicalUrl":"https://xoomar.com/markets/stocks/cccc"}],"updatedAt":"2026-11-05T12:37:46.786Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/cccc","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}